TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial

ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial.

PRNewsWire • 4 hours ago

TransMedics: Italian NOP Program Reinforces Huge International Opportunity

TransMedics: Italian NOP Program Reinforces Huge International Opportunity

Seeking Alpha • Feb 3, 2026

These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More

Traders targeting heavily shorted stocks are looking to play one of two sides: betting on a company's downfall or hunting for a short squeeze.

Benzinga • Feb 2, 2026

These under-the-radar stocks combine fast growth with big upside potential

The companies are projected to grow sales rapidly through 2027, and many of the stocks are expected to show double-digit increases this year.

Market Watch • Jan 15, 2026

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TMDX gains momentum as OCS technology, a robust pipeline and strong Q3 results fuel growth, though gross margin pressure tempers the outlook.

Zacks Investment Research • Jan 14, 2026

TransMedics Group, Inc. (TMDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

TransMedics Group, Inc. (TMDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

TransMedics: Strong Growth And A Better Setup

I see a clear path for TransMedics to deliver at least mid-20% revenue growth in 2026, with upside as year-over-year comparisons get easier. I believe operating margins will continue to expand as scale improves and the bulk of U.S. infrastructure spending moves into the rearview mirror. I expect operating profits to grow faster than revenue, setting up improving free cash flow as 2026 progresses.

Seeking Alpha • Jan 13, 2026

TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts

ANDOVER, Mass., Jan. 12, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing of a long-term lease for its new global headquarters at Assembly Innovation Park in Somerville, as well as the acquisition of the adjacent land parcel to create an integrated TransMedics campus environment.

PRNewsWire • Jan 12, 2026

3 MedTech Stocks That Crushed the S&P 500 Over the Past Year

TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.

Zacks Investment Research • Jan 9, 2026

TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

ANDOVER, Mass., Dec. 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 44th Annual J.P.

PRNewsWire • Dec 30, 2025